An Open-Label, Chronic Exposure Evaluation of the Safety of CLONICEL (Clonidine HCl Sustained Release) in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD).

Trial Profile

An Open-Label, Chronic Exposure Evaluation of the Safety of CLONICEL (Clonidine HCl Sustained Release) in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD).

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2012

At a glance

  • Drugs Central nervous system stimulants; Clonidine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Addrenex Pharmaceuticals; Shionogi Pharma
  • Most Recent Events

    • 13 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 13 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top